quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 29, 2026

Valley National Bancorp outlines 11%-13% net interest income growth for 2026 amid core deposit momentum

View original at seekingalpha.com
Valley National Bancorp outlines 11%-13% net interest income growth for 2026 amid core deposit momentum Earnings Call Insights: Valley National Bancorp (VLY) Q4 2025 MANAGEMENT VIEW * Ira Robbins, President, CEO & Chairman, highlighted "record earnings in the fourth quarter of 2025 with net income of approximately $195…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • If no rate cuts occur, there would be approximately 0.5% to 1% headwind from net interest income

    80% confidence
  • Management is conservatively assuming modest spread compression in the net interest income forecast

    80% confidence
  • Adjusted return on average assets of 1.14% represents the highest level since Q4 2022

    80% confidence
  • Loan growth was strong, diverse and tightly aligned with relationship-focused strategy, with commercial real estate loans growing sequentially for the first time since Q2 2024

    80% confidence
  • Management feels very strong about the lift off in the beginning of 2026 with significant tailwinds

    80% confidence
  • Recent additions to teams in New Jersey, California and Florida have already generated loan and deposit activity

    80% confidence
  • If the economy stays in the current situation, the trend of classified asset improvement is expected to continue in 2026 and into 2027

    80% confidence
  • Net interest income will grow between 11% and 13% in 2026

    80% confidence
  • Strategic priorities for 2026 include igniting small business sales efforts, improving branch productivity and exploring new growth-oriented deposit niches

    80% confidence
  • Valley National exceeded expectations across all major metrics by year-end while strengthening capital and liquidity positions

    80% confidence
  • Benefits between now and end of 2026 will be fairly balanced between loan and deposit sides of balance sheet, with $1.8 billion of fixed rate loans maturing in 2026 at around 4.7% coming back on 150 to 200 basis points higher

    80% confidence
  • Core deposits grew nearly $4 billion or 9% year-over-year

    80% confidence
  • Valley National achieved record earnings in Q4 2025 with net income of approximately $195 million or $0.33 per diluted share

    80% confidence
  • First quarter tends to be somewhat softer as a result of lower day count, elevated payroll taxes within operating expenses and seasonal headwinds on both sides of the balance sheet

    80% confidence
  • Valley National expects mid-single-digit loan growth for 2026 supported by roughly 10% C&I growth, low single-digit CRE growth and mid-single-digit consumer and residential growth

    80% confidence
  • Medium and late-stage loan pipelines are exceptionally strong, up over $1 billion or nearly 70% from just a year ago

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Valley National Bancorp outlines 11%-13% net interest income growth for 2026 amid core deposit momentum — Source | Via News | pt.VIA.NEWS